Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Cash from Operations (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Cash from Operations for 2 consecutive years, with 13277000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations rose 9.46% to 13277000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 72365000.0, a N/A change, with the full-year FY2024 number at 57672000.0, up 18.44% from a year prior.
  • Cash from Operations was 13277000.0 for Q3 2025 at Pyxis Oncology, up from 17263000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 3007000.0 in Q2 2024 to a low of 22535000.0 in Q1 2025.